VIR BIOTECHNOLOGY, I

VIR
Delayed Quote. Delayed  - 10/18 04:00:00 pm
38.8USD -0.74%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 3 4115 068
Entreprise Value (EV)1 2 6754 400
P/E ratio -10,7x-51,5x
Yield --
Capitalization / Revenue 44,7x11,3x
EV / Revenue 35,0x9,77x
EV / EBITDA -9,17x-30,0x
Price to Book --
Nbr of stocks (in thousands) 127 389130 612
Reference price (USD) 26,838,8
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 76,4450
EBITDA1 -292-147
Operating profit (EBIT)1 -297-113
Operating Margin -389%-25,1%
Pre-Tax Profit (EBT)1 -299-90,7
Net income1 -299-97,0
Net margin -391%-21,5%
EPS2 -2,51-0,75
Dividend per Share2 --
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 737667
Leverage (Debt / EBITDA) 2,53x4,55x
Free Cash Flow1 -197-63,8
ROE (Net Profit / Equities) -52,4%-34,3%
Shareholders' equity1 570283
ROA (Net Profit / Asset) -41,7%-37,6%
Assets1 715258
Book Value Per Share --
Cash Flow per Share2 -1,60-0,07
Capex1 6,553,80
Capex / Sales 8,58%0,84%
Announcement Date 02/25/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 5 068 M $ -
Entreprise Value (EV) 4 400 M $ 4 310 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -51,5x -19,7x
Capitalization / Revenue 11,3x 11,8x
EV / Revenue 9,77x 10,2x
EV / EBITDA -30,0x -28,0x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -25,1% -60,5%
Operating Leverage (Delta EBIT / Delta Sales) 0,13x -28,1x
Net Margin (Net Profit / Revenue) -21,5% -62,9%
ROA (Net Profit / Asset) -37,6% -78,4%
ROE (Net Profit / Equities) -34,3% -110%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   0,84% 1,12%
Cash Flow / Sales -1,94% -1,21%
Capital Intensity (Assets / Sales) 0,57x 0,80x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend